Supplementary data from FBXO22 Possesses Both Protumorigenic and Antimetastatic Roles in Breast Cancer Progression

The Supplementary Information includes: Figure S1. The effects of FBXO22 on breast cancer cell proliferation and anchorage-independent 3D growth. Figure S2. FBXO22 promotes xenograft tumor growth of MDA-MB-231 cells in vivo. Figure S3. FBXO22 suppresses cell migration and invasion. Figure S4. The effects of FBXO22 on the expression levels of EMT markers. Figure S5. The effects of FBXO22 on the mRNA levels of SNAIL. Figure S6. Schematic diagram of the structural domains of FBXO22 and SNAIL proteins. Figure S7. Phosphorylation of SNAIL by GSK3β affects its stability and subcellular localization. Figure S8. The mutation pattern of FBXO22 in breast cancer. Figure S9. The effects of deletion of F-box domain or W52R mutation on subcellular localization of FBXO22 and protein stability of SNAIL. Figure S10. The proposed working model. Table S1. Characterization of clincopathological features of 164 primary breast cancer patients. Table S2. siRNA target sequences for GSK3β. Tables S3. Primers used for molecular cloning of expression vectors. Tables S4. Information of expression vectors used in this study. Tables S5. Information for primary antibodies used in this study. Tables S6. Primers used for qPCR analysis. Table S7. Correlation between FBXO22 expression and clincopathological factors in 164 primary breast cancer patients. Table S8. Multivariate analysis of clincopathological factors for OS and DFS in 164 primary breast cancer patients.